Oral etoposide for refractory or recurrent epithelial ovarian cancer

Journal of the Medical Association of Thailand

Volumn 92, Issue 11, 2009, Pages 1397-1405

  Thavaramara, Thaovalai ^a   Tangjitgamol, Siriwan ^a   Manusirivithaya, Sumonmal ^a   Leelahakorn, Surawute ^a  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

Author keywords

Epithelial ovarian cancer; Oral etoposide; Recurrent

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MEGESTROL ACETATE; MELPHALAN; OXALIPLATIN; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE OBSTRUCTION; LEUKOPENIA; LUNG INFECTION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OBSTRUCTIVE JAUNDICE; OVARY CANCER; OVERALL SURVIVAL; PLEURA EFFUSION; PNEUMONIA; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR SEEDING; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; OVARY TUMOR; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 75349085380     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7 (Suppl 5): 20-8.
3. Satthapong D, Tangjitgamol S, Manusirivithaya S, Pataradool K. Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer. J Med Assoc Thai 2007; 90: 411-9.
4. Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003; 21: 149s-67s.
5. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 60-3.
6. Seymour MT, Mansi JL, Gallagher CJ, Gore ME, Harper PG, Evans TR, et al. Protracted oral etoposide in epithelial ovarian cancer:a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69: 191-5.
7. Kavanagh JJ, Tresukosol D, De Leon CG, Edwards CL, Freedman RS, Hord M, et al. Phase II study of prolonged oral etoposide in refractory ovarian cancer. Int J Gynecol Cancer 1995; 5: 351-4.
8. Swenerton K, Muss HB, Robinson E. Salvage chemotherapy for refractory disease in ovarian cancer. In: Gershenson DM, McGuire WP, editors. Ovarian cancer: controversies in management. New York: Churchill Livingstone; 1998: 169-94.
9. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 2003; 90: S39-S44.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
11. Case AS, Rocconi RP, Partridge EE, Straughn JM Jr. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer. Gynecol Oncol 2007; 105: 223-7.
12. Rocconi RP, Case AS, Straughn JM Jr, Estes JM, Partridge EE. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer 2006; 107: 536-43.
13. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-10.
14. Alici S, Saip P, Eralp Y, Aydiner A, Topuz E. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am J Clin Oncol 2003; 26: 358-62.
15. Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101: 436-40.
16. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22.
17. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25: 2811-8.
18. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 130-5.
19. Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol Oncol 2003; 88: 118-22.
20. Davis-Perry S, Hernandez E, Houck KL, Shank R. Melphalan for the treatment of patients with recurrent epithelial ovarian cancer. Am J Clin Oncol 2003; 26: 429-33.
21. de Jong RS, Hofstra LS, Willemse PH, de Bruijn HW, de Vries EG, Boonstra H, et al. Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1997; 66: 197-201.